Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 3, 2021

Global clinical trials activity increases 0.1% in Q3 2021 over 4Q average

The global clinical trials activity saw an increase of 0.1% in Q3 2021, when compared with the rolling average of the last four quarters (Q3 2020 to Q2 2021), according to GlobalData.

Of the overall activity, industry sponsored trials accounted for a 47.1% share in Q3 2021, marking a decrease of 1.6% in the total share when compared with the four-quarter average.

Non-industry sponsored trials accounted for a 52.9% share of all the clinical trials globally in Q3 2021, marking an increase of 1.6% in the overall share when compared with the four-quarter average.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top therapy areas for industry and non-industry sponsored clinical trials in Q3 2021

Oncology was the leading therapy area for industry sponsored clinical trials in Q3 2021, accounting for a 30.4% share of all trials.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

This was followed by the following therapy areas: Infectious Disease with a 15.7% share, Central Nervous System with a 13.7% share, Gastrointestinal with a 6.9% share and Cardiovascular with a 6.6% share.

In the last four quarters, Oncology held a lead over other therapy areas for industry sponsored clinical trials with a 27.5% share, followed by Infectious Disease with a 19.2% share, Central Nervous System with a 13.4% share, Metabolic Disorders with a 7.8% share, and Cardiovascular with a 7.3% share.

Industry sponsored trials activity: 4-Quarter Avg. vs Q3 2021
Therapy Area 4-Quarter Avg. Q3 2021 Activity
Oncology 27.5% 30.4% Increase
Infectious Disease 19.2% 15.7% Decrease
Central Nervous System 13.4% 13.7% Increase
Gastrointestinal 6.0% 6.9% Increase
Cardiovascular 7.3% 6.6% Decrease
Metabolic Disorders 7.8% 6.6% Decrease
Immunology 5.2% 5.4% Increase
Respiratory 6.0% 5.1% Decrease
Musculoskeletal Disorders 3.9% 4.1% Increase
Dermatology 4.3% 3.9% Decrease
Hematological Disorders 2.7% 3.0% Increase
Ophthalmology 3.0% 2.7% Decrease
Genito Urinary System And Sex Hormones 2.6% 2.6% Decrease
Genetic Disorders 1.7% 1.9% Increase
Women’s Health 1.9% 1.9% Decrease
Ear Nose Throat Disorders 1.2% 1.3% Increase
Male Health 0.8% 0.8% Decrease
Hormonal Disorders 0.5% 0.6% Increase
Mouth and Dental Disorders 0.6% 0.6% Decrease
Non Malignant Disorders 0.2% 0.5% Increase
Nutritional Disorders 0.4% 0.2% Decrease

Central Nervous System was the leading therapy area for non-industry sponsored clinical trials in Q3 2021, accounting for a 25.2% share of all trials.

This was followed by the following therapy areas: Oncology with a 24.0% share, Infectious Disease with a 13.1% share, Cardiovascular with an 8.9% share, and Gastrointestinal with a 6.6% share.

In the last four quarters, Oncology System held a lead over others for non-industry sponsored clinical trials with an average share of 23.8%, followed by Central Nervous System with a 22.8% share, Infectious Disease with a 17.8% share, Cardiovascular with a 9.1% share, and Gastrointestinal with a 6.5% share.

Non-Industry sponsored trials activity: 4-Quarter Avg. vs Q3 2021
Therapy Area 4-Quarter Avg. Q3 2021 Activity
Central Nervous System 22.8% 25.2% Increase
Oncology 23.8% 24.0% Increase
Infectious Disease 17.8% 13.1% Decrease
Cardiovascular 9.1% 8.9% Decrease
Gastrointestinal 6.5% 6.6% Increase
Metabolic Disorders 5.0% 5.5% Increase
Musculoskeletal Disorders 5.0% 5.2% Increase
Women’s Health 4.1% 4.1% Decrease
Respiratory 4.9% 3.9% Decrease
Dermatology 2.7% 3.0% Increase
Genito Urinary System And Sex Hormones 2.9% 3.0% Increase
Hematological Disorders 2.7% 2.8% Increase
Immunology 3.4% 2.7% Decrease
Mouth and Dental Disorders 2.2% 2.7% Increase
Ophthalmology 1.8% 1.8% Decrease
Ear Nose Throat Disorders 1.0% 1.2% Increase
Hormonal Disorders 0.8% 1.0% Increase
Genetic Disorders 0.6% 0.8% Increase
Male Health 0.5% 0.5% Decrease
Nutritional Disorders 0.7% 0.5% Decrease
Non Malignant Disorders 0.4% 0.2% Decrease

Top regions in industry and non-industry sponsored clinical trials activity in Q3 2021

Asia-Pacific held the top position for industry sponsored clinical trials activity in Q3 2021 with a 47.1% share, compared to 52.8% in the last four quarters.

North America stood at second place with a 34.0% share in Q3 2021, over 33.4% in the last four quarters, followed by Europe with a 32.2% share in Q3 2021, as against 29.1% in the last four quarters.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Single country studies held an 84.3% share in industry sponsored clinical trials in Q3 2021 when compared with 82.7% of average recorded in the last four quarters. Multinational trials accounted for a 15.7% share in Q3 2021, as against the four-quarter average of 17.4%.

Asia-Pacific region held the top position in non-industry sponsored clinical trial activity in Q3 2021 with a 53.6% share, over 51.4% in the last four quarters.

North America held the second position with a 20.1% share in Q3 2021, over 17.2% in the last four quarters, followed by Middle East and Africa with a 14.6% share in Q3 2021, as against 15.1% in the last four quarters.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Single country studies held a 99.0% share for non-industry sponsored clinical trials in Q3 2021, compared to 98.7% in the last four quarters. Multinational trials accounted for a 1.0% share in Q3 2021, as against 1.3% in the last four quarters.

Industry and non-industry sponsored clinical trials by Phase in Q3 2021

Phase II trials outnumbered all other studies with a 39.3% share for industry sponsored trials in Q3 2021, compared to 35.6% average in the last four quarters.

The share of Phase I trials stood at 32.2% in Q3 2021, as against the four-quarter average of 35.1%. Phase III trials held a 17.3% share in Q3 2021, registering an increase of 0.6% over the last four quarters average, followed by Phase IV trials with an 11.2% share in Q3 2021, as against the four-quarter average of 12.6%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Phase II trials outnumbered all other trials with a 42.1% share for non-industry sponsored clinical trials in Q3 2021, compared to 44.4% in the last four quarters.

Phase IV trials stood at second place with a 22.1% share in Q3 2021, compared to 21.4% in the last four quarters. Phase III trials held a 19.2% share in Q3 2021, as against 18.3% in the last four quarters, followed by Phase I trials with a 16.6% share in Q3 2021 over 15.8% average recorded in the last four quarters.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

 

Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU